Home › Blog › Weight Loss › Wegovy Cardiovascular NHS

Wegovy Cardiovascular NHS 2026: NICE Approved Wegovy as a Heart Medicine — 1.2 Million Newly Eligible

Overview: The April 2026 NICE Cardiovascular Approval

In April 2026, NICE made one of the most significant decisions in the history of obesity medicine in the UK: it officially approved Wegovy (semaglutide) as a cardiovascular medicine — not just a weight loss medication. This is a fundamentally different approval to the existing Wegovy weight management NICE guidance (TA875), and it opens NHS access to an entirely new population of patients.

The basis for this approval is the SELECT trial — a landmark cardiovascular outcomes study that showed Wegovy reduces major adverse cardiovascular events (heart attack, stroke, and death from cardiovascular causes) by 20% in adults with existing cardiovascular disease and overweight or obesity, without type 2 diabetes.

Approximately 1.2 million people in England have existing cardiovascular disease and a BMI of 27 or above — and are now newly eligible for NHS Wegovy under this cardiovascular indication. NHS trusts are required to make it available within 90 days of final NICE guidance — meaning availability is rolling out from approximately July–August 2026 in most areas.

What Changed in April 2026: A Clear Explanation

Before April 2026, NHS Wegovy was only available through one route: specialist tier 3 weight management services, under NICE TA875, for patients with a BMI of 35 or above with at least one weight-related condition. This route primarily targeted obesity with comorbidities.

The April 2026 approval is a separate, distinct NICE guidance covering a completely different indication: secondary cardiovascular prevention. This means using Wegovy to prevent further cardiovascular events — heart attacks and strokes — in people who have already had one.

The two distinct NHS Wegovy pathways now

The critical difference is the BMI threshold. The cardiovascular pathway requires only BMI 27 or above — which is the overweight threshold, not the obesity threshold. This means patients who have previously been told they are “not obese enough” for NHS Wegovy may now qualify through the cardiovascular route if they have existing heart disease.

The SELECT Trial: The Evidence Behind This Approval

The April 2026 NICE approval is based on the SELECT trial — the largest cardiovascular outcomes trial ever conducted for a weight loss medication. Published in the New England Journal of Medicine in 2023, SELECT enrolled 17,604 adults with established cardiovascular disease, overweight or obesity (BMI 27+), and without type 2 diabetes.

SELECT trial results

The 20% relative risk reduction in MACE is the headline result — but what matters clinically is the absolute risk reduction. Participants at highest cardiovascular risk benefited most. For a patient who has already had a heart attack, a 20% reduction in the risk of another cardiovascular event is a clinically profound benefit that has nothing to do with their BMI or weight loss goals.

Who Now Qualifies for NHS Wegovy Under the Cardiovascular Indication

Here is the complete eligibility picture for the new cardiovascular indication. This is separate from the existing weight management criteria under NICE TA875.

You likely qualify for NHS Wegovy (cardiovascular indication) if you have ALL of:

• BMI of 27 or above (overweight or obese) — or the adjusted lower threshold for specific ethnic groups
• Established cardiovascular disease — specifically one of:
  • Previous heart attack (myocardial infarction)
  • Previous stroke or TIA (transient ischaemic attack)
  • Established peripheral arterial disease
• No type 2 diabetes — the SELECT trial population and the NICE guidance covers patients without T2D. Patients with T2D have separate pathways for GLP-1 medications.
• Age 45 or over — the SELECT trial enrolled patients 45 and over; NICE guidance is likely to reflect this

You do NOT qualify under this specific guidance if you have:

• BMI below 27
• No history of heart attack, stroke/TIA, or peripheral arterial disease
• Type 2 diabetes (separate guidance applies)
• Absolute contraindications to semaglutide (MTC history, MEN2, pregnancy)

Ethnic group adjusted BMI thresholds

For South Asian, Chinese, Middle Eastern, Black African and African-Caribbean backgrounds, the BMI threshold is adjusted downward. Under the cardiovascular indication, the adjusted threshold is likely BMI 25 or above with established cardiovascular disease — consistent with the NICE approach to ethnic group BMI adjustments across other weight management guidance. Confirm with your GP.

The 1.2 Million: Who Are These Patients?

The estimate that approximately 1.2 million people in England are newly eligible under the cardiovascular indication comes from combining NHS cardiovascular disease prevalence data with BMI distribution statistics. Here is how that population breaks down:

This is a genuinely large population — and a population that has historically had very limited access to pharmacological weight management, because their BMI was often 27–34 (overweight but not classified as obese under previous criteria). For these patients, the cardiovascular benefit of Wegovy is directly relevant to their most pressing health risk.

How to Access NHS Wegovy for Cardiovascular Disease

The access pathway for the cardiovascular indication is through your GP — not through tier 3 weight management services. This is a critical difference from the obesity weight management pathway and makes it significantly more accessible in practice.

Step 1: Check your eligibility

Review the criteria above. You need: BMI 27+, established cardiovascular disease (previous heart attack, stroke, or PAD), and no type 2 diabetes.

Step 2: Book a GP appointment

Unlike NHS Mounjaro for obesity (where patients are advised not to request by name), the cardiovascular indication pathway is a GP prescribing decision. You can and should discuss it directly with your GP. Take a list of your cardiovascular history and current medications.

Step 3: What to say to your GP

“I’ve read about the new NICE guidance approving Wegovy for people with cardiovascular disease. I had a [heart attack/stroke/TIA] in [year] and my BMI is [X]. I’d like to discuss whether I might be eligible for NHS semaglutide (Wegovy) under the new cardiovascular indication.”

Step 4: GP assessment

Your GP will review your cardiovascular history, current medications, BMI, contraindications, and any relevant blood tests. If you are eligible under the new guidance and your GP practice is ready to prescribe, they can initiate treatment directly without tier 3 referral.

Step 5: Prescription and dispensing

If prescribed, the standard NHS prescription charge of £9.90 per pen applies (unless you are exempt from prescription charges).

The 90-Day Implementation Rule: When Will It Be Available?

NHS England requires NHS trusts to make newly NICE-approved treatments available within 90 days of the final guidance date. The April 2026 NICE guidance means NHS trusts must have processes in place for Wegovy cardiovascular prescribing by approximately July–August 2026.

Why there may still be delays

• Local formulary inclusion may take time — most trusts have formulary governance processes that NICE approval must go through
• GP system alerts and prescribing templates may not yet be updated
• Some ICBs may be managing supply and patient volume concerns before opening up prescribing widely
• GPs may need to be updated on the new pathway through practice-level communications

If your GP is not yet set up to prescribe, private Wegovy at Slinic (from £99.99/pen) is available now with no waiting — and switching to NHS supply when it becomes available in your area is straightforward.

Wegovy vs Mounjaro for Cardiovascular Patients

One of the most common questions from cardiovascular patients is: if Mounjaro is more effective for weight loss, why is Wegovy the one with the cardiovascular label?

For cardiovascular patients specifically: Wegovy is currently the right choice

If you have established cardiovascular disease and your primary goal is reducing future cardiovascular risk, Wegovy is the evidence-based choice. It has the formal cardiovascular benefit label. It is the medication NICE has approved for this indication. Mounjaro’s cardiovascular outcomes data is promising but the label is not yet granted.

If maximum weight loss is your primary goal alongside cardiovascular protection, this is a clinical conversation worth having with your Slinic prescriber — both the evidence and the cost picture will be relevant to the right recommendation for your individual circumstances. See our Mounjaro vs Wegovy comparison guide.

Private Wegovy While You Wait for NHS Access

For cardiovascular patients who qualify under the April 2026 NICE guidance but cannot access NHS Wegovy yet — either because their GP practice is not yet set up or because they do not want to wait — private Wegovy at Slinic is available now.

Why private makes sense for some cardiovascular patients

• The cardiovascular benefit in SELECT was clear at 33-month average follow-up — the sooner treatment starts, the sooner that benefit begins accumulating
• NHS implementation may take months in some areas even with the 90-day rule
• Private Wegovy at Slinic starts at £99.99/pen — the 2.4mg maintenance dose is £209.99 per month — significantly less expensive than Mounjaro
• Starting private does not affect NHS eligibility — you can transition to NHS supply as soon as it becomes available in your area

Slinic’s Wegovy prices

Scotland, Wales and Northern Ireland

What This Means Clinically: Beyond Just Eligibility

The April 2026 NICE cardiovascular approval represents more than just expanded eligibility — it is a paradigm shift in how GLP-1 medications are understood in UK healthcare.

Wegovy is now a cardiovascular medicine, not just a weight loss drug

The SELECT trial showed that Wegovy reduces cardiovascular events independently of the amount of weight lost. This means it is being approved for patients with BMI 27 — who might be classified as “merely overweight” rather than obese — because the cardiovascular benefit justifies prescribing even at that lower body mass. Weight loss is a beneficial side effect in this indication, not the primary goal.

Implications for prescribing practice

GPs and cardiologists now have a licensed, NICE-approved tool to reduce cardiovascular recurrence risk in a population of 1.2 million patients. For patients on statins, antihypertensives, and antiplatelet therapy following cardiovascular events, Wegovy adds a new evidence-based layer of secondary prevention. The clinical conversation about Wegovy is no longer purely a weight management conversation — it is a cardiovascular risk conversation.

What about patients who have cardiovascular disease AND obesity?

Patients with both established cardiovascular disease and significant obesity (BMI 30+) may qualify under either the cardiovascular indication (NICE April 2026) or the weight management indication (NICE TA875). In practice, the cardiovascular pathway may be more accessible because it goes through GPs directly rather than through tier 3 services. Your GP will consider which pathway is most appropriate for your individual clinical situation.

The Clinical Context: Why This Approval Is Historic

To understand why the April 2026 NICE cardiovascular approval matters so much, it helps to understand the history of how obesity treatment has been perceived in UK healthcare.

For decades, obesity was treated primarily as a lifestyle issue — a consequence of poor diet and insufficient exercise rather than a complex chronic disease with metabolic, hormonal, and neurological drivers. Pharmaceutical intervention for obesity was marginal and often viewed with scepticism. Weight loss medications were prescribed cautiously, with short-term approvals and limited NHS funding.

The SELECT trial changed everything. By demonstrating that a weight-related medication reduces cardiovascular death, heart attacks, and strokes by 20% in a randomised controlled trial of 17,604 patients, it reframed GLP-1 medications from weight loss tools to cardiovascular medicines with weight loss as a beneficial side effect. NICE’s April 2026 approval of Wegovy as a cardiovascular medicine reflects this reframing at the policy level.

Why BMI 27 is the threshold — not 30

The SELECT trial enrolled patients with BMI 27 or above — not just those with BMI 30+ (the conventional obesity threshold). This reflects a growing recognition that cardiovascular risk is not neatly divided at any single BMI number. Patients with BMI 28 who have already had a heart attack face a high risk of future events — and the SELECT data shows they benefit from semaglutide regardless of whether their BMI would traditionally classify them as “obese.” NICE’s decision to approve at BMI 27+ reflects this evidence faithfully.

What this means for how GPs now talk about weight

Before April 2026, a GP seeing a post-myocardial infarction patient with BMI 29 would typically discuss statins, antiplatelets, and ACE inhibitors as secondary prevention tools. Wegovy was not part of that conversation. From April 2026, it should be. The NICE approval gives GPs a mandate — and clinical backing — to discuss semaglutide as a cardiovascular secondary prevention option alongside existing medications.

Wegovy Drug Interactions for Cardiovascular Patients

Cardiovascular patients typically take multiple medications — statins, antiplatelets, antihypertensives, anticoagulants. Here is how Wegovy interacts with each common cardiovascular drug class.

What Monitoring Is Required for Cardiovascular Patients on Wegovy

Cardiovascular patients starting Wegovy require appropriate monitoring that reflects both the GLP-1 medication class effects and the cardiovascular comorbidity context.

Recommended monitoring framework

• Blood pressure — at every monthly check-in. Significant weight loss may reduce blood pressure, potentially allowing antihypertensive dose reduction
• Lipid profile (fasting) — at baseline and at 6–12 months. Significant weight loss typically improves lipid profiles; statin dose may be reviewable
• Kidney function (eGFR) — particularly important if on diuretics or if experiencing significant GI side effects causing dehydration
• INR (if on warfarin) — more frequent monitoring when starting Wegovy and when dose escalations occur
• Weight and waist circumference — at every monthly check-in to document cardiovascular risk reduction
• Cardiac symptoms — any new or worsening chest pain, palpitations, or breathlessness should be reported to the GP, not just the Wegovy prescriber

Beyond SELECT: Other Evidence for GLP-1s and Cardiovascular Health

While SELECT is the trial that earned Wegovy its cardiovascular label, the cardiovascular evidence for GLP-1 medications more broadly is growing rapidly. Understanding the full picture helps patients and clinicians contextualise the April 2026 approval.

SUSTAIN-6 (semaglutide, lower dose)

An earlier cardiovascular outcomes trial for semaglutide at lower doses used in diabetes management showed a 26% reduction in MACE — including a significant reduction in stroke. This provided early evidence that the cardiovascular effect was real and not a trial artefact.

LEADER (liraglutide — Saxenda’s mechanism)

The LEADER trial showed that liraglutide (Saxenda’s mechanism) also reduces cardiovascular events in patients with T2D and cardiovascular disease. This suggested a class effect rather than a semaglutide-specific benefit.

SURPASS-CVOT (tirzepatide — Mounjaro)

Eli Lilly’s cardiovascular outcomes trial for tirzepatide is ongoing. Interim data is described as showing positive signals, with final results expected in 2026–2027. If positive and submitted to MHRA and NICE, Mounjaro could eventually receive its own cardiovascular indication — potentially challenging Wegovy’s current unique position in this space.

The emerging consensus

The weight of evidence points increasingly toward a genuine cardiovascular protective effect from GLP-1 receptor agonism — not just as a consequence of weight loss (which accounts for only part of the benefit) but through direct anti-inflammatory, vasculoprotective, and cardiac remodelling mechanisms. The April 2026 NICE approval for Wegovy is the first formal UK acknowledgment of this at the prescribing level.

Real Patient Scenarios: Do You Qualify?

Cost Analysis: NHS vs Private for Cardiovascular Patients

For cardiovascular patients considering whether to wait for NHS access or start privately, here is the full cost picture.

The NHS cost saving (~£2,021/year) is substantial and clearly favours waiting for NHS access where possible. For patients who cannot wait — either because local GP pathways are not yet set up or because their cardiovascular risk makes immediate treatment start clinically compelling — private Wegovy at Slinic from £99.99/pen is available now, and transitioning to NHS supply when available is simple and straightforward.

More Questions Answered

Frequently Asked Questions

What to Do Right Now: Your Step-by-Step Action Plan

If you have cardiovascular disease and a BMI of 27 or above, here is your concrete action plan.

Option A: Pursue NHS access (recommended if you can wait)

1. Book a GP appointment now — request a cardiovascular risk review
2. Bring your full cardiovascular history — diagnosis dates, current medications, most recent BP and weight
3. Ask specifically: “I understand NICE has approved semaglutide (Wegovy) for people who have had a heart attack or stroke with a BMI of 27+. Am I eligible and is your practice ready to prescribe?”
4. If your GP is not yet set up — ask them to check with the local ICB medicines management team. The 90-day rule means they should be by July–August 2026.
5. If your local pathway is delayed — consider starting private at Slinic now and transitioning to NHS when available.

Option B: Start private at Slinic now

1. Complete the free 2-minute eligibility assessment at slinic.co.uk
2. Declare your cardiovascular history and all current medications — clinically essential for safe prescribing
3. If approved, first Wegovy pen dispatched within 24 hours
4. Inform your GP that you are taking Wegovy privately
5. Transition to NHS supply when available — your Slinic clinician can provide a treatment summary

Starting sooner is clinically logical for cardiovascular patients — the SELECT trial showed benefit at an average 33-month follow-up. Every month of proven cardiovascular risk reduction medication that a qualifying patient does not take is a month of potential benefit foregone.

Key Points Summary

• NICE approved Wegovy as a cardiovascular medicine in April 2026 — based on the SELECT trial’s 20% MACE reduction
• Approximately 1.2 million people in England are newly eligible — those with established CVD and BMI 27+, without T2D
• NHS trusts must implement within 90 days — access expected from July–August 2026
• Access is through GPs directly — NOT through tier 3 weight management services
• This is separate from and additional to the existing Wegovy obesity weight management pathway (NICE TA875)
• Wegovy is the only UK medication with a formal NHS cardiovascular benefit label — Mounjaro’s cardiovascular outcomes data is positive but not yet labelled
• Private Wegovy at Slinic (from £99.99/pen) is available now for eligible patients who cannot wait
• Starting private does not affect NHS eligibility — transition is straightforward when NHS access opens

The Future Cardiovascular Landscape for GLP-1 Medications

The April 2026 NICE cardiovascular approval for Wegovy is almost certainly not the last major development in this space. Here is what to watch for over the next 12–24 months that could further transform cardiovascular access to GLP-1 medications in the UK.

Mounjaro cardiovascular outcomes data (2026–2027)

Eli Lilly’s SURPASS-CVOT and related cardiovascular outcomes programme is expected to report in 2026–2027. If the results confirm a cardiovascular benefit comparable to or greater than SELECT — which some analysts expect, given Mounjaro’s superior metabolic profile — Mounjaro could seek and receive both MHRA and NICE cardiovascular labelling. This would create competition between tirzepatide and semaglutide on both weight loss efficacy and cardiovascular benefit.

Retatrutide cardiovascular outcomes (2027–2028)

Eli Lilly’s TRIUMPH-Outcomes trial for retatrutide — the triple GLP-1/GIP/glucagon agonist that produced 28.3% average weight loss in TRIUMPH-1 — is running simultaneously with its weight management trials. If retatrutide receives MHRA approval and subsequently demonstrates cardiovascular benefit, the cardiovascular medication landscape will expand further. See our retatrutide UK guide for the complete pipeline picture.

Expansion of the cardiovascular indication

The current April 2026 NICE guidance covers patients without type 2 diabetes — reflecting the SELECT trial population. Future NICE guidance may cover cardiovascular patients with T2D, or widen to include patients with cardiovascular risk factors (rather than just established disease). The SELECT-type evidence model may also be applied to the higher Wegovy 7.2mg dose or to other GLP-1 formulations as data matures.

What this means for patients now

For cardiovascular patients considering whether to start Wegovy now or wait for a potentially better medication: the evidence for Wegovy’s cardiovascular benefit is established and NICE-approved now. Retatrutide may produce greater weight loss when it arrives in 2027–2028 — but “waiting for something better” means months or years without proven cardiovascular risk reduction from an already-approved medication. The clinical advice is the same as for weight management: the best medication is the one that is available, safe, and appropriate for you today. Wegovy fills that role for cardiovascular patients right now.

The Numbers: Is It Worth Starting Private Before NHS Access Opens?

A simple calculation for cardiovascular patients weighing up private vs waiting for NHS:

For a patient whose GP practice implements the NHS pathway in July 2026, the cost of 1–2 months of private Wegovy at Slinic at the starting dose (£99.99–£109.99/month) while waiting is modest relative to the clinical benefit of starting treatment sooner. Many patients in this situation choose to start at the lowest dose privately, then transition to NHS at that same dose when the pathway opens — paying approximately £200–£300 for 2 months of benefit rather than waiting 2 months with no treatment.

Quick Self-Check: Do You Qualify for the Cardiovascular Indication?

Answer these four questions. If all are YES, you likely qualify for NHS Wegovy under the April 2026 cardiovascular indication (or private Wegovy at Slinic immediately):

1. Have you had a heart attack, stroke, TIA, or been diagnosed with peripheral arterial disease? — YES needed
2. Is your BMI 27 or above? (approximately: 5’4″ and 79+ kg · 5’6″ and 84+ kg · 5’8″ and 89+ kg) — YES needed
3. Do you NOT have type 2 diabetes? — YES needed (T2D patients have separate pathways)
4. Are you 18 or over and not pregnant or breastfeeding? — YES needed

If all four answers are YES: book a GP appointment to discuss NHS Wegovy, and/or complete Slinic’s free 2-minute assessment for immediate private access at slinic.co.uk. If you answered NO to question 3 (you have T2D): ask your GP about the separate GLP-1 cardiovascular pathway for T2D patients. If you answered NO to question 2 (BMI below 27): you do not currently qualify for either the cardiovascular or standard weight management pathway. Discuss cardiovascular risk reduction with your cardiologist or GP.

References

1. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM, 2023;389(24):2221-2232.
2. NICE. Semaglutide for secondary prevention of cardiovascular events. April 2026. nice.org.uk
3. NICE TA875 — Semaglutide for managing overweight and obesity. 2023.
4. NHS England. Implementation of NICE technology appraisals — 90-day funding rule. england.nhs.uk
5. GPhC guidance for online pharmacies. Updated February 2025. pharmacyregulation.org

Related Guides